ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR005

Intradialytic Hypertension Frequency and Short-Term Clinical Outcomes among Hemodialysis Patients

Session Information

Category: Dialysis

  • 606 Dialysis: Epidemiology, Outcomes, Clinical Trials - Cardiovascular

Authors

  • Assimon, Magdalene M., University of North Carolina, Chapel Hill, North Carolina, United States
  • Flythe, Jennifer E., University of North Carolina, Chapel Hill, North Carolina, United States
Background

Intradialytic hypertension (ID-HTN) occurs in 5-20% of hemodialysis treatments. Observational data support an association between ID-HTN and increased long-term mortality. However, the short-term cardiovascular (CV) consequences of recurrent ID-HTN are unknown.

Methods

Data were taken from a cohort of prevalent hemodialysis patients receiving treatment at a large U.S. dialysis organization on 01/01/2010. Using a retrospective cohort design with a 180-day baseline, 30-day exposure assessment and 30-day follow-up period, we estimated the association between ID-HTN frequency and: 1) 30-day mortality and 2) 30-day hospitalizations. We defined ID-HTN frequency during the 30-day exposure period as the proportion of hemodialysis treatments with a pre- to post-dialysis systolic blood pressure (BP) rise >0 mmHg. Multivariable Cox proportional hazards models, adjusting for numerous clinical, laboratory and dialysis treatment covariates, were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

Of 37,094 study patients, 5,242 (14%), 17,965 (48%), 10,821 (29%), 3,066 (8%) had ID-HTN in 0%, 1-32%, 33-66% and ≥67% of exposure period treatments, respectively. More frequent ID-HTN was associated with incremental increases in 30-day mortality and volume overload hospitalizations (Figure). Patients with ID-HTN in ≥67% (vs. 0%) of exposure period treatments had the highest risk of all-cause death, adjusted HR [95% CI]: 2.6 [1.7-3.9]; CV death, 3.7 [1.9-7.1]; and volume overload hospitalizations, 2.3 [1.3-4.2]. Analogous incremental associations were observed for all-cause and CV hospitalizations. In sensitivity analyses, use of alternative BP thresholds (≥5 and ≥10 mmHg) to define ID-HTN yielded similar results (data not shown).

Conclusion

Among prevalent hemodialysis patients, ID-HTN frequency is incrementally associated with short-term morbidity and mortality. Randomized trials are needed to determine if ID-HTN frequency mitigation improves patient outcomes.

Funding

  • NIDDK Support